[Responsiveness of parathyroid hormone secretion to a phosphate load in hypertensive patients with non insulin dependent diabetes mellitus]

What Was Tested

This controlled clinical trial paper looks at Parathyroid Hormone (PTH 1-84).

Abnormalities in calcium phosphate (Ca-P) metabolism and Ca-P related hormones are well documented in patients with essential hypertension (EH), but less in patients with non insulin dependent diabetes mellitus (NIDDM).

Who Took Part

The abstract describes 29 patients taking part.

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

In 29 patients in NTS group (45.6 +/- 1.3 y), 32 in CNT group (48.4 +/- 0.9 y) and in 23 healthy subjects-GK (42.7 +/- 2.7 y) - 25-OH-D(3), intact PTH, ionized (Ca(2+)) and phosphate (P) were estimated in blood serum before and PTH in 4, 8, 12, 18 and 24 hours, Ca(2+) and P in 2, 4, 6, 8, 10, 12, 18 and 24 hours after an oral administration of Pi.

How the Study Was Run

Urinary excretion of calcium and phosphate were also estimated on day before and at the day of an oral Pi load.

What Was Measured

The subject headings attached to it are Area Under Curve, Calcium, Cholecalciferol, Diabetes Mellitus, Type 2, Hypertension, Parathyroid Hormone and Phosphates.

What This Means in Plain Language

This is a controlled clinical trial of Parathyroid Hormone (PTH 1-84) in 29 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (Endokrynologia Polska), a journal based in Poland.

More context: the Parathyroid Hormone (PTH 1-84) compound page, all human trials.